March 18 (Reuters) – Pfizer Inc said on Friday its Xeljanz rheumatoid arthritis drug succeeded in meeting primary and secondary goals of a pair of late stage clinical trials in ulcerative colitis,…
The post Pfizer’s Xeljanz meets goals in ulcerative colitis trials appeared first on NASDAQ.